SEC Form 4/A · accession 0001209191-18-029589
Biohaven Pharmaceutical Holding Co Ltd. · BHVN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
James Engelhart
Officer — Chief Financial Officer
Period of report
Nov 9, 2017
Accepted (ET)
May 11, 2018 · 4:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001689813
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | holding | — | — | — | 3,038 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $0.61 | Nov 10, 2017 | M | 8,400 | D | — | Nov 25, 2024 | Common Shares | 8,400 | 32,500 | D |
Explanation of responses
- F1The shares underlying this option vested as to 25% of the shares on November 26, 2014, with the remainder vesting in 3 equal installments on the first, second and third anniversaries of the grant date, subject to the reporting person's continued service as of each applicable vesting date.
Remarks
This Form 4/A is being filed to amend the Form 4 filed with the Securities and Exchange Commission on November 14, 2017 to (i) reflect the exercise of 8,400 Table II options on November 10, 2017 instead of 8,938 options and the number of options owned following the reported transaction; and (ii) to reflect the total number of Table I shares owned following the reported transactions as 3,038 shares instead of 3,576 shares.